Clinical Trial Update: A Multicenter, Randomized, Double-blind, Placebo-parallel-controlled Phase II Clinical Study Evaluating the Efficacy and Safety of HRS9531 Injection in Obese Subjects With Polycystic Ovary Syndrome [Phase 2]

View source ↗

Summary

A Phase 2 randomized, double-blind, placebo-controlled trial evaluating HRS9531 for obesity-related polycystic ovary syndrome is currently not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Polycystic Ovary Syndrome

Drugs mentioned

• HRS9531 Injection (HRS9531)

Snippet

Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. | Conditions: Obese Subjects With Polycystic Ovary Syndrome (PCOS) | Phase 2 | Status: NOT_YET_RECRUITING